Disposition of 2200 shares by Malik Fady Ibraham of Cytokinetics at 10.6 subject to Rule 16b-3
| CYTK Stock | USD 62.02 0.14 0.23% |
About 55% of Cytokinetics' investor base is interested to short. The analysis of the overall investor sentiment regarding Cytokinetics suggests that many traders are impartial. Cytokinetics' investing sentiment shows overall attitude of investors towards Cytokinetics.
Cytokinetics | Build AI portfolio with Cytokinetics Stock |
Filed transaction by Cytokinetics Officer: Evp Research & Development. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at finance.yahoo.com
 |
Cytokinetics Fundamental Analysis
We analyze Cytokinetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Cytokinetics is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Cytokinetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cytokinetics stock to make a market-neutral strategy. Peer analysis of Cytokinetics could also be used in its relative valuation, which is a method of valuing Cytokinetics by comparing valuation metrics with similar companies.
Peers
Cytokinetics Related Equities
| HALO | Halozyme Therapeutics | 1.61 | ||||
| AXSM | Axsome Therapeutics | 0.43 | ||||
| JAZZ | Jazz Pharmaceuticals | 0.12 | ||||
| MRUS | Merus BV | 0.10 | ||||
| RYTM | Rhythm Pharmaceuticals | 0.06 | ||||
| CRSP | Crispr Therapeutics | 0.50 | ||||
| NUVL | Nuvalent | 2.23 | ||||
| ABVX | Abivax SA | 5.88 | ||||
| CORT | Corcept Therapeutics | 7.08 |
Check out Cytokinetics Hype Analysis, Cytokinetics Correlation and Cytokinetics Performance. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.